Xconomy

APRIL 5, 2018

As a showdown stockholders meeting draws near for San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), a proxy battle is boiling down to an argument over who represents the best interests of shareholders in the tiny RNA drug company. In an April 3 letter addressed to the company’s four board members, Arcturus co-founder and ex-CEO Joseph E.

Arcturus 49

Arcturus San Diego Company Companies 49

Xconomy

MARCH 29, 2018

The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. In a lawsuit filed Tuesday (see below) and in an open letter to shareholders issued Wednesday , the Arcturus (NASDAQ: ARCT ) board ­says a pattern of alleged misconduct, deceit, and failed leadership by Payne led to his termination on January 25. Payne, who.

Arcturus 49

Arcturus San Diego Develop Development 49

Xconomy

MAY 22, 2018

After postponing a May 7 shareholder vote in a power struggle for control of San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), the company’s board of directors has set a new date for its showdown with ousted CEO Joseph Payne. In a statement Monday, Arcturus said it has rescheduled its special shareholder meeting for 10 a.m.

Arcturus 40

Arcturus San Diego Blogging Startup 40

socalTECH

SEPTEMBER 3, 2010

Santa Monica-based TrueCar.com , the online automotive pricing startup headed up by Scott Painter, said Thursday that it has launched a new tool to help new car buyers. The firm is venture backed by Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, and GRP Partners. READ MORE>>.

Truecar 154

Truecar Pricing Tool Arcturus 154

socalTECH

JUNE 19, 2009

San Diego-based Sorrento Therapeutics , a new biotechnology startup, has raised $2.3M Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom.

Arcturus 100

Arcturus San Diego Venture Capital Equity 100

Xconomy

MARCH 2, 2018

Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. billion, a figure compiled in the Venture Monitor Report.

Funding 52

Funding Report Startup Venture Capital 52

Xconomy

FEBRUARY 9, 2018

Added up, the highly anticipated data led to a small stock dip and lots. First, Bristol changed the trial’s structure midstream. Second, it still hasn’t proven whether the combination helps patients more than its immunotherapy drug nivolumab (Opdivo) used alone. More results are still to come.

Help 58

Help Develop Development Arcturus 58

Xconomy

MARCH 30, 2018

in the first quarter was up 44 percent compared to the same period a year ago, according to data compiled by consulting and accounting firm EY. If the recent IPO activity seems to be on overdrive, it’s not your imagination. The number of companies filing to go public in the U.S.

Activity 52

Activity Report Marketing Company 52

Xconomy

JUNE 1, 2018

For the next five days, the oncology community’s attention will focus on Chicago. The Windy City is the home for the American Society of Clinical Oncology’s annual meeting, and it kicks off today. Many ASCO attendees will zero in on potential cancer drug combinations.

News 55

News Arcturus San Diego Blogging 55